Ly­me vac­cine test com­ple­tion is pushed back by a year as Pfiz­er, Val­ne­va say they'll ad­just tri­al

Val­ne­va and Pfiz­er have ad­just­ed the end date for the Phase III study of their in­ves­ti­ga­tion­al Ly­me dis­ease vac­cine, push­ing it back by a year af­ter is­sues at a con­tract re­searcher led to thou­sands of US pa­tients be­ing dropped from the test.

In a March 20 up­date to clin­i­cal­tri­als.gov, Val­ne­va and Pfiz­er moved the pri­ma­ry com­ple­tion date on the tri­al, called VAL­OR, from the end of 2024 to the end of 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER